GleamWall
中文EN

TSHA Taysha Gene Therapies, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1806310 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-13.1%
TTM net income YoY-56.1%
TTM EPS YoY-27.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2,935.4%
Net margin-2,844.6%
FCF margin-2,582.6%
EBITDA margin-2,913.6%

Returns

ROE-54.2%
ROA-41.5%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets17.9%
Debt / equity0.13x
Current ratio18.56x
Interest coverage-5,193.77x

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue13.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$9.77M$8.33M
R&D expense$86.40M$66.00M
SG&A expense$33.87M$28.95M
Operating income-$110.50M-$91.46M
Interest expense$63,000$102,000
Income tax$0$0
Net income-$109.00M-$89.30M
EBITDA-$109.35M-$90.21M
EPS (basic)-0.34-0.36
EPS (diluted)-0.34-0.36
Weighted avg. shares (diluted)319.71M250.13M
Balance sheet
Cash & equivalents$319.77M$139.04M
Current assets$324.65M$142.13M
PP&E, net$6.74M$7.49M
Total assets$343.32M$160.36M
Current liabilities$26.55M$26.23M
Long-term debt$50.11M$43.94M
Total debt$50.11M$43.94M
Total liabilities$96.38M$88.84M
Shareholders' equity$246.94M$71.53M
Net debt-$269.66M-$95.09M
Shares outstanding285.05M204.94M
Cash flow statement
Operating cash flow-$93.09M-$81.22M
Capital expenditure$738,000$374,000
Free cash flow-$93.83M-$81.60M
Investing cash flow-$604,000-$363,000
Financing cash flow$274.59M$76.68M
Depreciation & amortization$1.15M$1.25M
Stock-based compensation$13.30M$13.10M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.